News

Filter

Current filters:

HematologySobi

Sobi pays $10 million to exercise opt-in right for Elocta

Sobi pays $10 million to exercise opt-in right for Elocta

21-11-2014

Nordic biotech firm Swedish Orphan Biovitrum will exercise its opt-in right to take over final development…

Biogen IdecElocateEloctaFinancialHematologyPharmaceuticalSobiSweden

SOBI and Pharming extend and amend Ruconest agreement

SOBI and Pharming extend and amend Ruconest agreement

13-10-2014

Biotech companies Pharming Group and Swedish Orphan Biovitrum have amended and extended the Ruconest…

BiotechnologyHematologyMarkets & MarketingPharmingRuconestSobiSweden

Swedish Orphan Biovitrum adds new molecule to its hemophilia collaboration with Biogen Idec

Swedish Orphan Biovitrum adds new molecule to its hemophilia collaboration with Biogen Idec

19-09-2014

Nordic biotech firm Swedish Orphan Biovitrum has added the preclinical fusion molecule rFVIIIFc-XTEN-vWF…

Biogen IdecBiotechnologyHematologyLicensingSobiSweden

Swedish company Dilaforette announces Sobi’s Christina Herder as new CEO

22-01-2014

Swedish drug development company Dilaforette has named Christina Herder as its new chief executive.

BoardroomDilaforetteHematologyNorthern EuropePharmaceuticalSobi

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI

10-12-2013

This year’s American Society of Hematology (ASH) meeting continued yesterday with more clinical trial…

Biogen IdecEloctateHematologyJakaviNovartisPharmaceuticalResearchSobiTakeda PharmaceuticalsUSA

Biogen and SOBI announce top line results for hemophilia A treatment Eloctate

Biogen and SOBI announce top line results for hemophilia A treatment Eloctate

14-11-2013

US biotech major Biogen Idec (Nasdaq: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) have announced detailed…

Biogen IdecBiotechnologyEloctateHematologyNorth AmericaResearchSobiUSA

COMPANY SPOTLIGHT

Menarini

Back to top